Integrated nanosystem for macrophage-targeted delivery
SignaBlok’s proprietary nanosystem for delivery of drugs and/or imaging agents targets macrophages, inflammatory cells that are involved in virtually all inflammatory diseases and disorders. The system enables diagnostic...
Drug discovery platform for peptides with dual therapeutic modality
SignaBlok's proprietary drug discovery platform enables discovery and development of combinatorial inhibitory SCHOOL peptides with dual therapeutic mechanisms of action for applications in the diseases where dual therape...
Multi-modal (CT, MRI, PET, fluorescence) imaging platform for detection of TREM-1 expression
SignaBlok's proprietary multi-modal platform enables discovery and development of contrast agents and fluorescent probes as companion diagnostics (theranostics) for targeted imaging of TREM-1 expression in inflammatory d...
TREM-1 platform for oncology, immunology, and autoimmune
Ligand-independent mechanisms of TREM-1 blockade and excellent safety and tolerability of SignaBlok's first-in-class TREM-1 therapy minimize risk of drug failure in the clinic. In oncology, TREM-1 therapy suppresses inf...
delivered to your inbox.